Russian drugmaker Polysan will invest about 4 billion roubles (~$60 million) in the establishment of… To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space. Or, if you're only interested in reading the content about a specific topic (generics, biosimilars, coronavirus/COVID-19, digital pharma, Asia Pacific), then you can take our £10 per month channel subscription offer, which gives you access to all our news articles and in-depth content on this subject.
Russian pharmaceutical producer Polysan will invest about RUB4bn (about 4 billion roubles) in the full-cycle production of German drug firm Bayer's anticoagulant Xarelto (rivaroxaban). The two companies previously partnered in 2015 on the production of Gadovist, Magnevist and Ultravist at Polysan's St Petersburg facility. The latest collaboration will also see Polysan's antiviral treatment Cytoflavin manufactured at the plant.